Biogen Inc Cmn (BIIB) 246.13 $BIIB 4 Stocks That Crushed

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 11:12 PM

Biogen Inc Cmn (BIIB) 246.13 $BIIB

4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 246.13 (-4.33), BMRN: 81.10 (-1.84), SRPT: 19.95 (-1.04), ALXN: 135.61 (-2.63), IBB: 267.60 (-5.98), REGN: 372.03 (-9.05)

The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 6.32 (-0.24), BIIB: 246.13 (-4.33), IDRA: 1.50 (-0.07), RTRX: 17.40 (-0.30), ACOR: 27.07 (-0.45)

New Data Presented at the Annual European Congress of Rheumatology (EULAR 2016) Demonstrate Safety and Efficacy of Biogen's Anti-TNF Biosimilars Portfolio
BusinessWire - Thu Jun 09, 6:08AM CDT
Data demonstrating long-term comparable efficacy, safety and immunogenicity of BENEPALI(R) (etanercept) and FLIXABI(R) (infliximab) were presented by Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen (NASDAQ: BIIB), at the Annual European Congress of Rheumatology (EULAR 2016), held 8-11 June in London, UK. Results showed that in patients who were switched from the reference product Enbreli to BENEPALI, there were no treatment-emergent safety or immunogenicity issues, and efficacy was sustained for up to two years.ii Comparable safety, immunogenicity and sustained efficacy were also demonstrated in patients who were switched from Remicadeiii to FLIXABI, compared with those who continued on Remicade.iv BENEPALI and FLIXABI were both approved by the European Commission (EC) earlier this year and are commercialized in Europe by Biogen.
BIIB: 246.13 (-4.33)

Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 246.13 (-4.33), SRPT: 19.95 (-1.04), ALXN: 135.61 (-2.63), AMGN: 154.78 (-2.00), ABBV: 61.00 (+0.25), REGN: 372.03 (-9.05), CELG: 102.91 (-3.22)

Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 6.32 (-0.24), BIIB: 246.13 (-4.33), IDRA: 1.50 (-0.07), RTRX: 17.40 (-0.30), LGND: 113.74 (-1.34), ACOR: 27.07 (-0.45)

Stock Market News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Benchmarks closed mostly in the green on Tuesday following gains in energy stocks
BIIB: 246.13 (-4.33), VRTX: 91.49 (-1.00), PXD: 159.55 (-4.65), ALXN: 135.61 (-2.63), HAL: 44.38 (-1.12), EOG: 81.56 (-3.02), AMGN: 154.78 (-2.00), ILMN: 141.62 (-1.80), XOM: 89.98 (-0.69), COP: 44.51 (-2.06), JUNO: 42.98 (-2.55), CVX: 101.98 (-0.83), OXY: 75.45 (-0.15), REGN: 372.03 (-9.05)

Oil Bears Have Lost Their Bite – It’s Time for Energy Stocks to Soar
Greg Guenthner - Daily Reckoning - Wed Jun 08, 8:29AM CDT
This post Oil Bears Have Lost Their Bite – It’s Time for Energy Stocks to Soar appeared first on Daily Reckoning . Nineteen measly points. That’s all that separates the S&P 500 from topping its all-time closing highs. But not all...
BIIB: 246.13 (-4.33)

Why is Biogen (BIIB) Stock Plunging Today?
Madeleine Johnson - Zacks Investment Research - Tue Jun 07, 3:04PM CDT
On Tuesday, shares of biopharmaceutical company Biogen (BIIB) are plunging, down over 15% in afternoon trading after the company???s Phase 2 study of its treatment for relapsing multiple sclerosis failed to meet its primary and secondary endpoints.
BIIB: 246.13 (-4.33)

SmarTrend Watching for Potential Rebound in Shares of Biogen Idec After 11.93% Loss
Comtex SmarTrend(R) - Tue Jun 07, 11:47AM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $250.87 to a high of $264.73. Yesterday, the shares fell 11.9%, which took the trading range below the 3-day low of $283.79 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 246.13 (-4.33)

Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 11.93%
Comtex SmarTrend(R) - Tue Jun 07, 11:45AM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $250.87 to a high of $264.73. Yesterday, the shares fell 11.9%, which took the trading range below the 3-day low of $283.79 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 246.13 (-4.33)

Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
BusinessWire - Tue Jun 07, 6:30AM CDT
-- Biogen Continues to Analyze Data to Inform Next Step in Clinical Development Program --
BIIB: 246.13 (-4.33)

Kite (KITE) and Biogen's Drugs Included in PRIME Initiative
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 4:55PM CDT
Kite Pharma, Inc. (KITE) announced that its immuno-oncology candidate, KTE-C19, has been granted access to the Priority Medicines (PRIME) regulatory initiative in Europe.
BIIB: 246.13 (-4.33), KITE: 51.30 (-2.12), PFE: 35.29 (-0.02), BMY: 72.65 (-0.08)

The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
BIIB: 246.13 (-4.33), SRPT: 19.95 (-1.04), ICPT: 150.66 (-3.56), ABBV: 61.00 (+0.25), IONS: 21.75 (+0.30)

Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 246.13 (-4.33), VRTX: 91.49 (-1.00), GILD: 84.45 (-1.32), SRPT: 19.95 (-1.04), ICPT: 150.66 (-3.56), ABBV: 61.00 (+0.25), IONS: 21.75 (+0.30)

Biogen's Investigational Alzheimer's Disease Treatment Aducanumab Accepted into European Medicines Agency's PRIME Program
BusinessWire - Wed Jun 01, 10:45AM CDT
Today Biogen (NASDAQ:BIIB) announced that aducanumab, its investigational treatment for early Alzheimer's disease (AD), was accepted into the European Medicines Agency's (EMA) PRIority MEdicines (PRIME) program. PRIME aims to bring treatments to patients faster by enhancing the EMA's support for the development of investigational medicines for diseases without available treatment or in need of better treatment options.
BIIB: 246.13 (-4.33)

Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 2.77%
Comtex SmarTrend(R) - Tue May 31, 12:23PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $284.66 to a high of $291.63. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $284.28 on volume of 922,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 246.13 (-4.33)

Roche's Subcutaneous Formulation of MabThera Gets EU Nod
Zacks Equity Research - Zacks Investment Research - Tue May 31, 9:10AM CDT
Roche (RHHBY) announced that the EC has approved the subcutaneous formulation of MabThera (rituximab) for the treatment of patients suffering from previously untreated and relapsed/refractory CLL.
BIIB: 246.13 (-4.33), PFE: 35.29 (-0.02), BMY: 72.65 (-0.08)

Biogen Receives Positive CHMP Opinion for TYSABRI(R) (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy
BusinessWire - Tue May 31, 6:30AM CDT
The Committee of Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a variation to the marketing authorization of TYSABRI(R) (natalizumab), Biogen (NASDAQ: BIIB) announced today. The CHMP recommends the approval of TYSABRI for use as a disease modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS) patients with highly active disease activity despite a full and adequate course of treatment with at least one DMT. The positive opinion is supported by long-term real-world experience from the TYSABRI Observational Program (TOP), an ongoing observational, open-label, 10-year prospective study of RRMS patients.
BIIB: 246.13 (-4.33)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RAI's TrustX Lab Unveils AI Assurance Framework

Pushing the Envelope on AI Control Alright, AI wonks, the Responsible AI Institute just introduced a new sheriff in town. It's called the TrustX Assurance Lab, and it was rolled out during RAISE 2026. We're talking about an independent setup designed to answer whether autonomous AI can stay within its limits. Who's involved? A lot of brainpower from member organizations...

Navigating Car Wreck Chaos for Legal Protection

Clarity Amid Chaos: Handling a Crash in Abilene Let me tell you, if your day starts with a car wreck, every second post-crash counts more than you think. Attorney Chaile Allen out of Abilene's laying down the law on how to protect yourself—because that wreck scene ain't just about bent fenders and bruised egos. It's about getting your ducks in a row for any potential...

Bluerock's Split: What November's Trading Change Means

Bluerock's Strategic Move: Untying the Bundle Ah, Bluerock Acquisition Corp. II has thrown a new bone to the market. Starting November 16, 2026, the firm ain't keeping their Class A ordinary shares and warrants locked in a bundle anymore. This shift comes after they sold 17,250,000 units in their IPO back in September, which also saw underwriters fully clinking their...

Inflatable Wonders Turn Christmas into a Hoot at Lowe's

Inflatables Bringing the Cheer (and Laughs) Well, it's that season again—where decorations either have us grumbling at the electric bill or chuckling at the lawn art. Lowe's has teamed up with Gemmy to serve a heaping platter of holiday giggles this year. They've rolled out a quirky lineup of inflatables that go from shivering Highland cows to dinosaurs and elves....

Sound Credit Union, WTA Team Up for Trail Support

Heading Into the Great Outdoors with Every Swipe You ever feel like your money's going nowhere useful? Well, folks in Washington are about to flip the script thanks to Sound Credit Union and the Washington Trails Association (WTA). They've cooked up a slick new money move—a co-branded debit and credit card program—where every swipe backs the state's beloved trails. A...

China-Kenya Trade: Avocado Diplomacy in Action

Avocado: A Trade Symbol with a Pit of Potential Who'd have thought a simple avocado could become such a heavyweight in the international trade arena? But here we are, with Kenyan avocados making a splash on the grand stage at the ninth China International Import Expo in Shanghai. Thanks to zero-tariff treatment, Kenya's prized green exports are rolling into China easier...

Sands China Fosters Cultural Ties with Macau Concert

Macao's Wind Music Legacy Hits a High Note Who would've thought—a gathering of 550 musicians from Macao SAR and France could ignite such a dynamic cross-cultural exchange? Celebrating three decades of musical milestones, the Macau Band Directors Association (MBDA) didn't just throw any old concert but a spectacle that took international collaboration to an upscale...

Yeastar 2026 Summit: AI, Growth, and Global Vision

Reflecting on Two Decades of Innovation Yeastar's 20th anniversary summit in Xiamen was no ordinary gathering. It wasn't just about handshakes and business cards. Nope, it was a celebration intertwined with a deeper vision of growth and influence in the UCaaS space that Yeastar has carved out for itself over the years. Here's a company that's been plotting its course for...

Fake Profiles Dominate Daters' Trust Issues Today

Trust Erosion in the Digital Dating Arena When it comes to modern dating, we're not talking hearts and flowers anymore; it's more like an elaborate game of detective work. A recent survey from Stud or Dud highlights the harsh reality that blind trust in digital dating profiles is about as outdated as sending a singing telegram. Almost half of the respondents pinned fake...

Angels on Call: Leading Dementia Care Recognition

A Milestone in Dementia Care Excellence Angels on Call Homecare has done what no other U.S. homecare provider seems to have managed—nab recognition from the Alzheimer's Association Curriculum Review while also holding the Purple Flag accreditation. That's a combo meal of accolades in the world of dementia care, and it speaks volumes about their commitment to top-notch...